Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: A Spanish multicenter retrospective study

European Journal of Haematology

Volumn 85, Issue 4, 2010, Pages 363-365

  De La Rubia, Javier ^a,b   Roig, Mónica ^a   Ibáñez, Ángela ^c   García, Inmaculada ^d   Vera, José A ^e   Aguilar, Carlos ^f   Del Campo, Raquel ^g   González, Nicolás ^h   Martínez, Rafael ⁱ   Palomera, Luis ^j   Picón, Isabel ^k   Rodríguez, Juan N ^l   Sanz, Miguel A ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b UNIVERSIDAD CATÓLICA DE VALENCIA SAN VICENTE MÁRTIR   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALBACETE   (Spain)

^d HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^e HOSPITAL UNIVERSITARIO VIRGEN MACARENA   (Spain)

^f HOSPITAL SANTA BÁRBARA   (Spain)

^g HOSPITAL SON LLÀTZER   (Spain)

^h HOSPITAL OBISPO POLANCO   (Spain)

ⁱ HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^j HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^k INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^l HOSPITAL JUAN RAMÓN JIMÉNEZ   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DEXAMETHASONE; LENALIDOMIDE; THALIDOMIDE;

AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MULTIPLE MYELOMA; PATHOLOGY; PATHOPHYSIOLOGY; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; DEXAMETHASONE; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; RENAL DIALYSIS; RETROSPECTIVE STUDIES; THALIDOMIDE; TREATMENT OUTCOME;

EID: 77956949045     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2010.01500.x     Document Type: Letter

References (9)

1. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007 357 : 2123 2132.
2. Weber D, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma in North America. N Engl J Med 2007 357 : 2133 2142.
3. Dimopoulos MA, Christoulas D, Roussou M, et al. Lenalidomide and dexamethasone fir the treatment of refractory/relapsed multiple myeloma: dosing of lenalidomide according to renal function and effect on renal impairment. Eur J Haematol 2010 85 : 1 5.
4. Durie B, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006 20 : 1467 1473.
5. Tosi P, Zamagni E, Cellini C, Tacchetti P, Tura S, Baccarani M, Cavo M. Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure. Eur J Haematol 2004 73 : 98 103.
6. Harris E, Behrens J, Samson D, Rahemtulla A, Russell NH, Byrne JL. Use of thalidomide in patients with myeloma and renal failure may be associated with unexplained hyperkalaemia. Br J Haematol 2003 122 : 160 161.
7. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S. Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study. Blood 2007 109 : 2604 2606.
8. Niesvizky R, Naib T, Christos PJ, et al. Lenalidomide-induced myelosuppression is associated with renal dysfunction: adverse events evaluation of treatment-naive patients undergoing front-line lenalidomide and dexamethasone therapy. Br J Haematol 2007 138 : 640 643.
9. Niesvizky R, Jayabalan DS, Christos PJ, et al. BiRD (Biaxin [clarithromycin]/Revlimid (lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma. Blood 2008 111 : 1101 1109.